{"id":"iv-acetaminophen","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Infusion site reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1647","moleculeType":"Small molecule","molecularWeight":"327.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetaminophen works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering the pain threshold and resetting the hypothalamic thermostat. The intravenous formulation provides rapid systemic delivery for faster onset of analgesia and antipyresis compared to oral routes. The exact mechanism remains incompletely understood but does not involve significant peripheral anti-inflammatory activity like NSAIDs.","oneSentence":"Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:25.984Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management of mild to moderate pain"},{"name":"Management of moderate to severe pain with opioids"},{"name":"Fever reduction"}]},"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT06009926","phase":"PHASE2","title":"Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-04","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm","enrollment":72},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT07423650","phase":"PHASE4","title":"Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy","status":"RECRUITING","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2026-03","conditions":"Pancreatoduodenectomy, Pain Management, Opioid Analgesia","enrollment":93},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT06393374","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-24","conditions":"Triple-Negative Breast Cancer","enrollment":1530},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT06112548","phase":"NA","title":"The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA","status":"COMPLETED","sponsor":"Damascus University","startDate":"2024-03-01","conditions":"Arthritis Knee, Pain, Arthroplasty Complications","enrollment":80},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT02439034","phase":"PHASE2","title":"Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304)","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02","conditions":"Uterine Cervical Cancer, Upper Aerodigestive Tract Neoplasms","enrollment":68},{"nctId":"NCT06043323","phase":"PHASE2","title":"A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-08","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT05896228","phase":"PHASE2","title":"Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Benjamin T Diamond, MD","startDate":"2024-02-20","conditions":"Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":30},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT05597878","phase":"PHASE2, PHASE3","title":"Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy","status":"SUSPENDED","sponsor":"Wake Forest University Health Sciences","startDate":"2023-04-18","conditions":"Pain Management, Opioid Use, Prostate Cancer","enrollment":100},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT03695367","phase":"PHASE2","title":"Phase 2 Herniorrhaphy Study for Opioid Elimination","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2018-10-01","conditions":"Postoperative Pain","enrollment":63},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT07435493","phase":"NA","title":"Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstructive Sleep Apnea","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-11-30","conditions":"Adenotonsillectomy, Obstructive Sleep Apnea (OSA), Fentanyl","enrollment":64},{"nctId":"NCT07433231","phase":"NA","title":"Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients","status":"COMPLETED","sponsor":"Ayfer Kaya Gök","startDate":"2023-11-01","conditions":"Anesthesia Emergence Delirium, Adenotonsillar Hypertrophy","enrollment":100},{"nctId":"NCT06201676","phase":"PHASE4","title":"Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-02-28","conditions":"Orthopaedic Trauma, Chronic Opioid Use","enrollment":458},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT06994442","phase":"PHASE3","title":"Optimizing Pain Treatment in Children On Mechanical Ventilation","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-12-29","conditions":"Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid","enrollment":644},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07211399","phase":"EARLY_PHASE1","title":"Transition From Acute to Chronic Opioid Use and Chronic Pain","status":"NOT_YET_RECRUITING","sponsor":"Jacques E. Chelly","startDate":"2026-03-01","conditions":"Opioid Use Disorder","enrollment":700},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT06074588","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-12","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":556},{"nctId":"NCT06878014","phase":"PHASE4","title":"Comparing the Safety and Effectiveness of Different Doses of Morphine Administered in Spinal Anethesia for Pain Relief After Hip Replacement Surgery","status":"RECRUITING","sponsor":"Medical University of Silesia","startDate":"2025-03-04","conditions":"Analgesics, Opioid, Anesthesia, Spinal, Total Hip Replacement","enrollment":120},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT05488847","phase":"PHASE4","title":"Opioid-Free Pain Protocol After Shoulder Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2022-06-25","conditions":"Shoulder Arthropathy, Shoulder Pain","enrollment":83},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT07397117","phase":"NA","title":"Comparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-02-01","conditions":"Sciatica Acute","enrollment":100},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT07368738","phase":"PHASE4","title":"Intravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy","status":"NOT_YET_RECRUITING","sponsor":"Horizon Health Network","startDate":"2026-03","conditions":"Extracorporeal Shockwave Lithotripsy","enrollment":266},{"nctId":"NCT07368790","phase":"NA","title":"Elective Total Abdominal Hysterectomy With Preoperative Analgesia Intravenous Paracetamol Versus Placebo","status":"COMPLETED","sponsor":"Queen Savang Vadhana Memorial Hospital, Thailand","startDate":"2024-10-10","conditions":"Postoperative Pain","enrollment":40},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT04093219","phase":"PHASE3","title":"PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2020-08-11","conditions":"Delirium in Old Age, Delirium, Coronary Artery Disease","enrollment":900},{"nctId":"NCT06309693","phase":"NA","title":"Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2025-01-22","conditions":"Pelvic Organ Prolapse, Post Operative Pain","enrollment":70},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT07331441","phase":"NA","title":"External Oblique Intercostal Plane Block for Postoperative Analgesia After Major Upper Abdominal Surgery","status":"NOT_YET_RECRUITING","sponsor":"Jun Zhang","startDate":"2026-01-15","conditions":"Abdominal Surgery, Postoperative Pain","enrollment":78},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS","enrollment":14},{"nctId":"NCT04963296","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-26","conditions":"Systemic Lupus Erythematosus","enrollment":303},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT06460961","phase":"PHASE1","title":"A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-14","conditions":"Neoplasm Metastasis","enrollment":168},{"nctId":"NCT03978767","phase":"PHASE2","title":"Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-06-10","conditions":"Preeclampsia Severe, Preeclampsia Postpartum","enrollment":287},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT06298227","phase":"NA","title":"Erector Spinae Plane Block vs Quadratus Lumborum Block for Laparoscopic Nephrectomy","status":"RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2024-03-11","conditions":"Kidney Diseases, Kidney Failure","enrollment":60},{"nctId":"NCT07264309","phase":"NA","title":"Combined Intravenous Tramadol and Paracetamol Versus Intramuscular Pethidine for Pain Relief During the First Stage of Labor. Compare the Efficacy and Adverse Effects","status":"RECRUITING","sponsor":"Zohar Nachum","startDate":"2025-11-01","conditions":"Pain Management, Birth","enrollment":140},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":85},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT05065554","phase":"PHASE2","title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shayna Sarosiek, MD","startDate":"2021-11-16","conditions":"IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral","enrollment":12},{"nctId":"NCT05340582","phase":"PHASE2","title":"Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2022-12-12","conditions":"Patent Ductus Arteriosus After Premature Birth","enrollment":310},{"nctId":"NCT05035407","phase":"PHASE1","title":"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-08","conditions":"Kita-kyushu Lung Cancer Antigen 1, Human","enrollment":36},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT05279898","phase":"NA","title":"Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-02-28","conditions":"Postoperative Delirium, Hemodynamic Instability, Pain","enrollment":70},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus (SLE)","enrollment":196},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT04545424","phase":"PHASE2","title":"Trial of Therapeutic Hypothermia in Patients With ARDS","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-06-29","conditions":"Respiratory Distress Syndrome, Adult","enrollment":340},{"nctId":"NCT07225634","phase":"PHASE3","title":"A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain","status":"NOT_YET_RECRUITING","sponsor":"AFT Pharmaceuticals, Ltd.","startDate":"2026-02","conditions":"Acute Pain","enrollment":60},{"nctId":"NCT04668833","phase":"PHASE2","title":"ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-29","conditions":"Solid Tumor Malignancies","enrollment":26},{"nctId":"NCT05285813","phase":"PHASE2","title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-05-06","conditions":"AML, MDS","enrollment":42},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT03823534","phase":"PHASE3","title":"Post-Op Pain Control for Prophylactic Intramedullary Nailing.","status":"RECRUITING","sponsor":"St. Louis University","startDate":"2019-02-20","conditions":"Bone Metastases, Lymphoma, Multiple Myeloma","enrollment":60},{"nctId":"NCT06955741","phase":"PHASE1","title":"A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-05","conditions":"Healthy Volunteer","enrollment":46},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT03493945","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-01","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm","enrollment":59},{"nctId":"NCT03032601","phase":"NA","title":"Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis","status":"ENROLLING_BY_INVITATION","sponsor":"Thomas Jefferson University","startDate":"2017-01-05","conditions":"Multiple Sclerosis","enrollment":55},{"nctId":"NCT04294459","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-06-18","conditions":"Immune System Disorder","enrollment":23},{"nctId":"NCT05842044","phase":"PHASE2","title":"NSAID Use After Robotic Partial Nephrectomy","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-09-15","conditions":"Kidney Cancer, Renal Cancer, Renal Neoplasm","enrollment":110},{"nctId":"NCT07134660","phase":"NA","title":"Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-09-01","conditions":"Postoperative Pain, Acute, Lung Cancer","enrollment":210},{"nctId":"NCT05231460","phase":"PHASE4","title":"Pain Management Study","status":"ENROLLING_BY_INVITATION","sponsor":"University of Arizona","startDate":"2022-02-18","conditions":"Pain, Postoperative","enrollment":244},{"nctId":"NCT05779930","phase":"EARLY_PHASE1","title":"Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-10","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory","enrollment":12},{"nctId":"NCT07104097","phase":"NA","title":"Comparison Between 2 Techniques for Lumbar-ESPB","status":"NOT_YET_RECRUITING","sponsor":"Papa Giovanni XXIII Hospital","startDate":"2025-08-11","conditions":"Hip Surgery","enrollment":44},{"nctId":"NCT04240626","phase":"PHASE4","title":"Multimodal Analgesia Effect on Post Surgical Patient","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2021-01-20","conditions":"Obesity, Morbid, Surgery, Bariatric Surgery Candidate","enrollment":60},{"nctId":"NCT07109284","phase":"PHASE2","title":"SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-09","conditions":"ER+HER2- Breast Cancer","enrollment":55},{"nctId":"NCT06935331","phase":"PHASE4","title":"Prospective Opioid-Free AIS Fusion","status":"NOT_YET_RECRUITING","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2025-08-15","conditions":"Adolescent Idiopathic Scoliosis (AIS)","enrollment":58},{"nctId":"NCT06225466","phase":"PHASE4","title":"Muscle Relaxation for Pediatric Adenotonsillectomy","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-04-10","conditions":"Tonsillectomy","enrollment":172},{"nctId":"NCT03805932","phase":"PHASE1","title":"Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-03","conditions":"Hairy Cell Leukemia","enrollment":18},{"nctId":"NCT06174363","phase":"NA","title":"Analgesic Efficacy of Maxigesic in Breast Cancer Surgery","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-12-28","conditions":"Breast Cancer","enrollment":84},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT07067177","phase":"PHASE2, PHASE3","title":"Prophylactic IV Paracetamol in Extremely Premature Infants","status":"ENROLLING_BY_INVITATION","sponsor":"Al-Quds University","startDate":"2025-05-01","conditions":"Patent Ductus Arteriosus in Preterm Infants, Patent Ductus Arteriosus After Premature Birth, Patent Ductus Arteriosus (PDA)","enrollment":28},{"nctId":"NCT06950840","phase":"PHASE4","title":"Antipyretic Treatment for Intrapartum Fever: Dipyrone vs Acetaminophen (RCT)","status":"NOT_YET_RECRUITING","sponsor":"Wolfson Medical Center","startDate":"2025-08-01","conditions":"Intrapartum Fever, Chorioamnionitis","enrollment":140},{"nctId":"NCT03365622","phase":"PHASE4","title":"Efficacy of IV Acetaminophen Versus Oral Acetaminophen","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2018-08-08","conditions":"Nephrectomy","enrollment":214}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACCIDENTAL OVERDOSE"},{"count":1,"reaction":"ANAPHYLACTIC REACTION"},{"count":1,"reaction":"ANAPHYLACTIC SHOCK"},{"count":1,"reaction":"ATAXIA"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BREATH SOUNDS ABNORMAL"},{"count":1,"reaction":"BRONCHOSPASM"},{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"FACE OEDEMA"},{"count":1,"reaction":"FEELING HOT"}],"_approvalHistory":[],"publicationCount":201,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IV APAP","APAP","Ofirmev","1000mg IV Acetaminophen","Paracetamol"],"phase":"marketed","status":"active","brandName":"IV Acetaminophen","genericName":"IV Acetaminophen","companyName":"Mallinckrodt","companyId":"mallinckrodt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Management of mild to moderate pain, Management of moderate to severe pain with opioids, Fever reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}